* Avid Bioservices Inc CDMO.OQ reported a quarterly
adjusted
loss of 27 cents per share for the quarter ended October 31,
lower than the same quarter last year, when the company reported
EPS of -15 cents. The mean expectation of five analysts for the
quarter was for a loss of 12 cents per share. Wall Street
expected results to range from -15 cents to -9 cents per share.
* Revenue rose 31.9% to $33.50 million from a year ago;
analysts
expected $33.80 million.
* Avid Bioservices Inc's reported EPS for the quarter was a
loss
of 27 cents.
* The company reported a quarterly loss of $17.4 million.
* Avid Bioservices Inc shares had risen by 7.8% this
quarter and
gained 88.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "hold"
Wall Street's median 12-month price target for Avid Bioservices
Inc is $12.50
This summary was machine generated from LSEG data December 10 at
10:14 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Oct. 31 2024 -0.12 -0.27 Missed
Jul. 31 2024 -0.05 -0.09 Missed
Apr. 30 2024 -0.04 -1.94 Missed
Jan. 31 2024 -0.05 -0.09 Missed